In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today)
A new market report from BioWorld Today appraises the state and potential of the genomics technologies market allowing you to see where the trends are taking us for 2009. View more details here to get insight into these next-generation technologies.
In the early part of the 20th century, before the Depression and World War II, dozens of children lay comatose in hospital wards where hopeless families gathered awaiting their inevitable deaths. This was not cancer before chemotherapy, or tuberculosis before antibiotics. This was Type I diabetes before insulin. (BioWorld Financial Watch)
Novosom AG in-licensed from Isis Pharmaceuticals Inc. the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ transplant rejection. (BioWorld International)
Biofuels Are Driving Green Biotech to New Market Value — Biofuels has placed itself at the forefront of many government initiatives concerning biotechnology, transportation, oil, and energy. This new in-depth report provides forecasts well beyond current standard projections and identifies the growth potential through a variety of data. View a complete index of this report here.
